SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-24-105862
Filing Date
2024-04-23
Accepted
2024-04-23 07:00:54
Documents
13
Period of Report
2024-04-19
Items
Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

Document Format Files

Seq Description Document Type Size
1 8-K d804228d8k.htm   iXBRL 8-K 27506
  Complete submission text file 0001193125-24-105862.txt   147133

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA mcrb-20240419.xsd EX-101.SCH 2869
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE mcrb-20240419_lab.xml EX-101.LAB 17236
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE mcrb-20240419_pre.xml EX-101.PRE 10825
16 EXTRACTED XBRL INSTANCE DOCUMENT d804228d8k_htm.xml XML 3507
Mailing Address 200 SIDNEY STREET CAMBRIDGE MA 02139
Business Address 200 SIDNEY STREET CAMBRIDGE MA 02139 617 945 9626
Seres Therapeutics, Inc. (Filer) CIK: 0001609809 (see all company filings)

IRS No.: 274326290 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37465 | Film No.: 24862664
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)